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Abstract: Clinical practice research provides a unique opportunity to care for a diverse patient 
population in various health care system settings. Federal study of Adherence to Medications in 
the Elderly (FAME) was the ﬁ  rst prospective observational and randomized controlled trial to 
implement effective strategies to enhance medication adherence and health outcomes in older 
patients using polypharmacy. Ten lessons learned from conducting this adherence intervention 
trial are described: (1) Link the trial to existing clinical work, (2) Begin with a thorough under-
standing of medication adherence, (3) Ensure that trial highlights individualized intervention, 
(4) Tailor inclusion criteria and study duration to target population, (5) Employ a range of 
outcomes linked to meaningful clinical effects, (6) Win the support of the multidisciplinary 
team and the administration, (7) Promote team work, (8) Consider the potential limitations, 
(9) Seize the grant opportunities, and (10) Share the ﬁ  ndings.
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Clinical practice research provides a unique opportunity to care for a diverse patient 
population in various health care system settings. Such research can lead to strategic 
discoveries in improving medication delivery and patient safety. The Federal study 
of Adherence to Medications in the Elderly (FAME)1 was the ﬁ  rst clinical trial to 
adopt effective interventions to enhance medication adherence and health outcomes in 
older patients, tested via a prospective observational phase followed by a randomized 
controlled trial. A comprehensive pharmacy care program was developed using three 
key components: (1) an individualized education provided by clinical pharmacists, (2) an 
adherence aid (custom blister-packaging of medications), and (3) a serial follow-up 
schedule. After a six-month exposure to the comprehensive pharmacy care program 
(study phase 1), the subjects’ medication adherence increased from 61.2% (baseline) 
to 96.9% (p  0.001). The increased adherence rate was associated with signiﬁ  cant 
improvements in systolic blood pressure (BP) (133.2 to 129.9 mm Hg; p = 0.02) and 
low-density lipoprotein cholesterol (LDL-C) (91.7 to 86.8 mg/dL; p = 0.001). At 
the beginning of the study phase 2, all active patients were randomized to either the 
continued pharmacy care group or the usual care group. At the end of the six-month 
randomized trial, the pharmacy care group patients successfully achieved medication 
persistence (sustained adherence) at 95.5%; however, the usual care group patients’ 
adherence rate returned to near the baseline (69.1%; p  0.001). The medication 
persistence was associated with further reductions in systolic BP in the continued 
pharmacy care group.1
Many lessons were learned from conducting the FAME trial, while designing the 
intervention program; recruiting, enrolling, and retaining study patients; coordinating 
the blister-packing process; working with multidisciplinary providers and departments; 
obtaining a foundation grant; and presenting the study ﬁ  ndings. Ten lessons learned are Patient Preference and Adherence 2009:3 94
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described (see Table 1) to promote ongoing practice-based 
research to enhance medication adherence.
Link the trial to existing clinical 
work
Your patients’ speciﬁ  c needs, limitations in a health care 
system, or missing links to an optimal adherence pattern 
may be recognized in a daily clinical work and fuel research 
questions. In turn, innovative ways to fulﬁ  ll the identiﬁ  ed 
needs, to overcome the limitations, or to connect the missing 
links can serve as your research interventions. For example, 
after reviewing pharmacy notes from a geriatric clinic, it 
was evidenced that poor medication adherence was the most 
frequently identiﬁ  ed problem among our elderly patients. 
Of 308 patient encounters, only 40% of the patients were 
documented to be adherent. Besides providing pillboxes, our 
health care system offered no speciﬁ  c solution to nonadher-
ence. At the same time, a literature review revealed 65% of 
adults 65 years and older having two or more chronic health 
problems2 that often led to polypharmacy use, nonadherence, 
and hospitalization.3 Despite this well known problem in 
the elderly, there were no adherence interventions proven 
to be effective or widely in use. The need for adherence 
improvement in our patients and the lack of adherence 
strategies for older adults fueled the questions regarding 
possible interventions to enhance adherence and health care 
outcomes, which became the FAME research aims.
Begin with a thorough 
understanding of medication 
adherence
Before constructing an adherence intervention trial, 
investigators must first understand the definition of 
medication adherence and methods used for assessment. 
Medication adherence is a term describing a patient’s 
medication-taking behavior, generally deﬁ  ned as the extent 
to which a patient adheres to an agreed regimen derived by 
a collaboration between the patient and their health care 
provider.4–6 The word “adherence” is often preferred over 
“compliance” because medication compliance implies the 
patient passively complying to the provider’s medication 
orders with no attempts made at collaboration.4,6,7
There are numerous methods used to assess medication 
adherence in practice, including the subjective, direct, and 
indirect measures.4,8 An array of methods such as patient self-
report, pharmacy reﬁ  ll history, pill counts, serum drug level, 
etc. have been used. A single or a combination of these mea-
sures can be used in a trial. Employing a consistent method 
throughout a trial period is of importance. During FAME, 
adherence for all chronic medications was assessed using pill 
counts calculated as the number of pills taken (the number 
of pills dispensed relative to the number of pills remaining 
at follow-up).1 Even though pill counts can become labor-
intensive with a polypharmacy regimen, using the blister-
packs as an adherence aid eased this process in FAME.
Ensure that trial highlights 
individualized intervention
When designing an adherence study, seek to implement a 
creative and individualized intervention strategy to meet 
the speciﬁ  c needs of the target population. In general, a 
comprehensive intervention using cognitive and behavioral 
characteristics is most effective.9 Patient education, regarded 
as an essential initial step to ensuring adherence, has only a 
marginal and transient effect on medication adherence when 
used alone.10–12 Similarly, a meta-analysis of medication 
packaging alone suggested a slight increase in adherence 
rate in only half of the studies (all short-term) included.13 
In contrast to above studies, two studies that implemented 
complex intervention programs reported positive results for 
both the adherence and the clinical outcomes in hypertensive 
patients.14,15 Individualization of the adherence intervention to 
the intended trial population is essential. For instance, to serve 
the community dwelling elderly patients using polypharmacy, 
we employed a comprehensive intervention strategy. How-
ever, younger patients who are at lower risk for medication 
nonadherence, may not require such intensive program.
The FAME comprehensive pharmacy care program 
combined an individualized medication education with a 
provision of custom blister-packed medications and a serial 
follow-up with clinical pharmacists every two months.1 The 
individualized education was performed using a standardized 
Table 1 Ten lessons learned from conducting the Federal study of 
Adherence to Medications in the Elderly trial
  1  Link the trial to existing clinical work
  2  Begin with a thorough understanding of medication adherence
  3  Ensure that trial highlights individualized intervention
  4  Tailor inclusion criteria and study duration to target population
  5  Employ a range of outcomes linked to meaningful clinical effects
  6  Win the support of the multidisciplinary team and the administration
  7  Promote team work
  8  Consider the potential limitations
  9  Seize the grant opportunities
10  Share the ﬁ  ndingsPatient Preference and Adherence 2009:3 95
10 lessons learned from an adherence intervention trial
checklist of education component and tools used, in order to 
minimize the inter-rater variability among the pharmacists. 
The study pharmacists also tailored the patients’ medication 
regimen, taking into account their preferences and daily rou-
tine, any drug–drug or drug–food interactions, and adverse 
drug reactions. A personalized medication chart, updated at 
each study session, was provided to reinforce the teaching 
and to be used as a reference during all health care visits 
(Figure 1). Accordingly, all chronic medications were custom 
packaged in morning, noon, evening, and/or bedtime blis-
ter-packs for convenience, which allowed patients to easily 
access their medications and visually track adherence.1 The 
follow-up appointments were scheduled every two months, 
during which education and blister-packs were provided.
Tailor inclusion criteria and study 
duration to target population
Efforts were made to preserve generalizability of the study 
results, and to meet the power needed for valid outcomes 
when recruiting patients for FAME. A broad set of inclu-
sion criteria, consisting of men and women aged 65 years 
who used polypharmacy (four or more chronic medications), 
was chosen. A limited exclusion criteria of a presence of 
any condition that would make one-year survival unlikely 
was placed.1
Study duration is a balance among sample size, time 
required to demonstrate an effect of interventions, and risk 
of subject loss due to prolonged time to endpoint assessment. 
The randomized phase of the FAME trial provided insight 
into the required duration of an adherence intervention. 
Despite receiving six months of comprehensive interventions, 
the group randomized to resume usual care for six months 
reverted to near the original level of medication adherence. In 
contrast, the group randomized to receive continued pharmacy 
care sustained a high adherence rate, and was found to have 
further improvements in blood pressure.1 Thus, for a high-risk 
elderly population, as in FAME, adherence interventions 
need to continue long-term and perhaps indeﬁ  nitely. On the 
other hand, if an education session or an adherence aid alone 
motivates a low-risk patient group to optimal adherence, then 
an initial intervention and a follow-up appointment to assess 
the impact may sufﬁ  ce.
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Employ a range of outcomes linked 
to meaningful clinical effects
Prior to implementing an adherence trial, the focused 
population’s disease states should be evaluated and 
measurable outcomes selected. Connecting adherence 
changes to improved health outcomes is crucial for 
acceptance of the study results and translation of the results 
to practice. In FAME, a hypothesis was generated that older 
patients achieving higher rates of adherence would have 
better control of their hypertension and hyperlipidemia, 
the two most prevalent disease states in our patients. 
Hypertension and hyperlipidemia are also the conditions in 
which the drug effects are objectively measured and linked to 
patient outcomes.16,17 The FAME results showed that marked 
improvements in medication adherence not only equates to 
a 16-fold increase in proportion of the “adherent” patients 
(those who took at least 80% of all of their medications), but 
that these changes were associated with clinically-meaningful 
reductions in BP and LDL-C.1 Therefore, large gains in 
adherence are achievable with focused interventions and in 
turn lead to improved health outcomes.
Win the support of the 
multidisciplinary team 
and the administration
When conducting an adherence intervention trial within 
a health care system, it is vital to gain the support of the 
multidisciplinary team and the administration. A targeted 
education to providers who are in position to recognize 
nonadherence can accelerate study enrollment. Prior to and 
during the FAME recruitment, several in-services were given 
to inform the various providers about the patient inclusion 
criteria and the referral process. The majority of the FAME 
subjects were referred by their primary care providers, but 
professionals including social workers, nurses, psychologists, 
and nutritionists who attended the FAME in-service also 
referred patients to the program.
Winning the support of the administration is critical 
and inﬂ  uences the successful conduction of an adherence 
intervention trial. For the highly labor-intensive blister-
packing process and appointment booking for the study, 
the department of pharmacy provided us the space, durable 
equipments, and technician support as required. The facility’s 
laboratory performed the blood draws, analyzed the results, 
and reported LDL-C for the study subjects with an approval 
of the impact statement from the Department of Pathology 
and Laboratory Services. Do ensure that your objectives meet 
the overall mission of the institution in order to secure the 
support needed for a successful trial.
Promote team work
Although study pharmacists served an essential role in the 
FAME trial, the need for a teamwork approach to conquering 
nonadherence was strongly underscored. A couple of key 
partnerships were critical in carrying out the study. The coor-
dination of the FAME project prompted a paradigm shift in 
the outpatient pharmacy from a dispensing operation to a site 
of clinical pharmacy care. The blister-packing was conducted 
at the outpatient pharmacy, where the blister-packs were ﬁ  lled 
by the pharmacy technicians using a commercially available 
manual ﬁ  ll system and checked by the clinical pharmacists. 
Thus, the ongoing collaboration sustained this operation. 
Once the FAME program was initiated, the multidisciplinary 
clinicians gradually adopted and supported the program. 
Clear and open communications about the patients’ medica-
tion regimen and reconciliation facilitated this partnership.
Consider the potential limitations
There are several practical limitations to a wide-scale 
implementation of an adherence intervention trial that must 
be recognized and overcome, if possible, to ensure success.
•  In FAME, the study pharmacists were tasked with highly 
time-intensive duties including patient recruitment and 
consent, patient and provider education, medication 
regimen tailoring, data collection (pill counts, BP 
measuring, LDL-C ordering), and blister-packing 
oversight. The blister-packing process was particularly 
time-consuming due to the manual process. Future 
programs should consider using a technological 
automation, now available, to ease this task.
•  The FAME patients received all medications free of 
charge as part of their military health care beneﬁ  t.1 Ways 
to alleviate ﬁ  nancial burden should be explored for 
patients with minimal to no health care coverage. Medi-
cation provision through Medicare and patient assistance 
programs, and generic prescribing should be sought for 
such population.
•  Because of the nature of the interventions, blinding of 
study subjects or research personnel for adherence trials is 
often difﬁ  cult. However, concealed allocation during the 
randomization can be done via a central control of the ran-
domization sequence. Also, subjects can be assigned using 
the block randomization method to ensure an even alloca-
tion of the pivotal patient characteristics, such as the level 
of baseline adherence, which was done in FAME.1,18Patient Preference and Adherence 2009:3 97
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Seize the grant opportunities
The spark for FAME ideas was a competitive junior investigator 
grant awarded by the American Society of Health-System 
Pharmacists (ASHP) Research and Education Foundation. 
This grant program provided an opportunity for a junior phar-
macy investigator to work with a highly experienced senior 
researcher. The steps involved in grant writing, protocol 
approval, use of funds, trial implementation, publishing the 
ﬁ  ndings, and most importantly caring for the study patients 
were learned through the process. Submission of a quarterly 
research report was required by the granting body, which 
gave us a frequent chance to evaluate the study progression. 
The accountability supplied by a grant source can strengthen 
a study through the review process and the progress report 
requirement, and prevent projects from becoming unﬁ  nished.
There are several annual grant opportunities that can 
help stimulate adherence intervention trials. Following 
are examples of such opportunities geared towards new 
investigators and the related links:
•  ASHP Foundation: Junior Investigator Research Grant; 
Federal Services Junior Investigator Research Grant; 
Pharmacy Resident Practice-Based Research Grant. See 
http://www.ashpfoundation.org/MainMenuCategories/
ResearchResourceCenter/FosteringYoungInvestigators/
NewInvestigatorGrantPrograms.aspx.
•  American Pharmacists Association Foundation: Incentive 
Grants. See http://www.aphafoundation.org/programs/
Incentive_Grants/.
•  American College of Clinical Pharmacy Research 
Institute: Frontiers Career Development Research Award; 
Investigator Development Research Awards. See http://
www.accp.com/frontiers/research.php.
Share the ﬁ  ndings
Compared to the vast and expanding literature on the 
effectiveness of novel drugs, only a few prospective trials 
enhancing adherence to them has published to date. There is a 
lack of evidence from randomized trials.9 Following the initial 
presentation at the 2006 American Heart Association Scientiﬁ  c 
Sessions and the publication in the Journal of American 
Medical Association (JAMA),1 the impact of the FAME 
ﬁ  ndings was immediate. The work received broad attention 
in the national media including USA Today, Wall Street 
Journal and Reuters, in addition to over 400 print and online 
articles. A media presentation (ﬁ  lmed by the JAMAVISION, 
the video version of JAMA) sent to news outlets around 
the country was believed to have reached approximately 
4.5 million viewers and countless Internet views. FAME was 
one of the Medscape’s Top Ten Pharmacy News that year, 
and we received inquiries about implementation of similar 
programs from practitioners in health care systems around the 
world. The lesson here is that the success stories of adherence 
intervention trials impact, not only the targeted patients in the 
program, but also the multidisciplinary professionals and their 
patients globally, if they are shared.
Conclusion
Medication nonadherence, a prevalent and penetrating 
problem in today’s growing older population, inﬂ  uences 
health care providers, health care systems, third party payers, 
governmental agencies, and policy makers who converge on 
the issue of medication provision.19 Using the ten lessons 
described, pharmacists and other health care providers should 
develop and implement intervention trials to promote medica-
tion adherence. These trials must advance current knowledge 
regarding adherence through practical innovations, while 
maintaining the ultimate focus on the optimal patient care. 
When JAMAVISION came to ﬁ  lm the FAME pharmacy care 
program, a 92-year-old patient who took part in FAME was 
interviewed. She exclaimed without any hesitation, “I loved 
the FAME program … it made my life easy!”
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